Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00180544 · ClinicalTrials.gov registry record · Phase 3
Safety and Effectiveness Study of the HERCULINK 14 Stent to Treat Renal Artery Disease
A Phase 3 study, sponsored by Abbott Medical Devices.
- Terminated
- Registry status
- Phase 3
- Development phase
- 167
- Enrollment target
NCT00180544 is a Phase 3 study that was terminated before completion, run by Abbott Medical Devices. The registered enrollment target is 167 participants.
The verdict
NCT00180544, a Phase 3 study, was terminated before completion, sponsored by Abbott Medical Devices.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 167 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of the RX HERCULINK 14 Peripheral Stent System in treating atherosclerotic renal artery stenosis.
Interventions
- DEVICE Stenting: Renal Artery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2000-07 |
| Est. Completion | 2004-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00180544
The ClinicalTrials.gov registry entry for NCT00180544 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Stenting: Renal Artery is the first listed.
NCT00180544 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00180544 about?
NCT00180544 is a clinical study titled "Safety and Effectiveness Study of the HERCULINK 14 Stent to Treat Renal Artery Disease". The purpose of this study is to evaluate the safety and effectiveness of the RX HERCULINK 14 Peripheral Stent System in treating atherosclerotic renal artery stenosis.
What is the current status of trial NCT00180544?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 167 participants. The study started on 2000-07. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00180544?
The interventions under investigation include: Stenting: Renal Artery (DEVICE).
Who is sponsoring clinical trial NCT00180544?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.